US EditionHeidelberg Pharma announces financial figures and reports on successful business performance in 2024 – Optimum Strategic Communications
Summary by Optimum Strategic Communications
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Heidelberg Pharma announces financial figures and reports on successful business performance in 2024 – Optimum Strategic Communications
Promising data in the clinical trial with HDP-101 in multiple myeloma, including a complete remission in one patient; study progressing well First approvals for clinical trial with ATAC candidate HDP-102 received; study start soon Financial figures in line with plan with improved operating result and lower cash requirements Payment of USD 20 million from HealthCare […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
